Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taimur Sher

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood|July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomasUdit Yadav, Shaji K Kumar, Linda B Baughn, et al.
Mayo Clinic Proceedings|August 6, 2025
Heart Transplantation for Cardiac Amyloidosis: Mayo Clinic Consensus StatementMelissa A Lyle, Julie L Rosenthal, Jose N Nativi Nicolau, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
JAMA Oncology|January 6, 2017
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Blood|July 8, 2017
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaJonas Paludo, Joseph R Mikhael, Betsy R LaPlant, et al.
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood|July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomasUdit Yadav, Shaji K Kumar, Linda B Baughn, et al.
Mayo Clinic Proceedings|August 6, 2025
Heart Transplantation for Cardiac Amyloidosis: Mayo Clinic Consensus StatementMelissa A Lyle, Julie L Rosenthal, Jose N Nativi Nicolau, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
JAMA Oncology|January 6, 2017
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, et al.
Pageof 12